These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 488757)

  • 21. Antipyrine kinetics in liver disease and liver transplantation.
    Mehta MU; Venkataramanan R; Burckart GJ; Ptachcinski RJ; Yang SL; Gray JA; Van Thiel DH; Starzl TE
    Clin Pharmacol Ther; 1986 Apr; 39(4):372-7. PubMed ID: 3514052
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antipyrine clearance and metabolite formation: the influence of liver volume and smoking.
    Spoelstra P; Teunissen MW; Janssens AR; Weeda B; van Duijn W; Koch CW; Breimer DD
    Eur J Clin Invest; 1986 Aug; 16(4):321-7. PubMed ID: 3093244
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liver size in evaluating drug metabolizing capacity in man.
    Pirttiaho H
    Int J Clin Pharmacol Biopharm; 1979 Jun; 17(6):271-6. PubMed ID: 468452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antipyrine clearance and its correlation to routine liver function tests in patients with liver disease.
    Krausz Y; Zylber-Katz E; Levy M
    Int J Clin Pharmacol Ther Toxicol; 1980 Jun; 18(6):253-7. PubMed ID: 7450926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Liver blood flow, antipyrine clearance, and antipyrine metabolite formation clearance in patients with chronic active hepatitis and alcoholic cirrhosis.
    Bauer LA; O'Sullivan T; Reiss WG; Horn JR; Opheim K; Strandness DE; Carithers RL
    Br J Clin Pharmacol; 1994 Apr; 37(4):375-81. PubMed ID: 8018459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accuracy and clinical utility of simplified tests of antipyrine metabolism.
    Farrell GC; Zaluzny L
    Br J Clin Pharmacol; 1984 Oct; 18(4):559-65. PubMed ID: 6487495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The association between rifamycin-SV (R-SV) related hyperbilirubinaemia and antipyrine clearance as a new test of liver function in cirrhosis.
    Persico M; Romano M; Villano N; Montella F; Gentile S
    Eur J Clin Invest; 1994 Mar; 24(3):201-4. PubMed ID: 8033955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. One sample antipyrine clearance after 90% partial hepatectomy in the rat.
    Poulsen HE
    Liver; 1985 Aug; 5(4):200-4. PubMed ID: 4058272
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A re-evaluation of intersubject variation in enzyme induction in man.
    Branch RA; Shand DG
    Clin Pharmacokinet; 1979; 4(2):104-10. PubMed ID: 455871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug metabolism in diabetic subjects with fatty livers.
    Pirttiaho HI; Salmela PI; Sotaniemi EA; Pelkonen RO; Pitkänen U; Luoma PV
    Br J Clin Pharmacol; 1984 Dec; 18(6):895-9. PubMed ID: 6529530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antipyrine clearance per unit liver volume in cirrhotics with and without hepatocellular carcinoma indicating a correlation with histological change of the liver.
    Noda S; Kawata S; Miyoshi S; Minami Y; Tarui S
    Gastroenterol Jpn; 1989 Apr; 24(2):159-63. PubMed ID: 2545499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antipyrine and caffeine dispositions in clinically normal dogs and dogs with progressive liver disease.
    Boothe DM; Cullen JM; Calvin JA; Jenkins WL; Brown SA; Green RA; Corrier DE
    Am J Vet Res; 1994 Feb; 55(2):254-61. PubMed ID: 8172417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antipyrine clearance in chronic and neoplastic liver diseases: a study of 518 patients.
    Grieco A; Castellano R; Matera A; Marcoccia S; Di Rocco P; Ragazzoni E; Vecchio FM; Gasbarrini G
    J Gastroenterol Hepatol; 1998 May; 13(5):460-6. PubMed ID: 9641640
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elimination of pindolol in liver disease.
    Ohnhaus EE; Münch U; Meier J
    Eur J Clin Pharmacol; 1982; 22(3):247-51. PubMed ID: 7106158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Quantification of the drug-metabolizing enzyme system in liver diseases: a comparison between antipyrine saliva clearance and the aminopyrine breath test].
    von Mandach U; Jost G; Preisig R
    Schweiz Med Wochenschr; 1985 May; 115(19):651-8. PubMed ID: 3923620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationships among liver and kidney volumes, lean body mass and drug clearance.
    Nawaratne S; Brien JE; Seeman E; Fabiny R; Zalcberg J; Cosolo W; Angus P; Morgan DJ
    Br J Clin Pharmacol; 1998 Nov; 46(5):447-52. PubMed ID: 9833597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow.
    Branch RA; Shand DG; Wilkinson GR; Nies AS
    J Clin Invest; 1974 Apr; 53(4):1101-7. PubMed ID: 4205524
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Value of liver volume measurement in the study of antipyrine kinetics in liver disease [proceedings].
    Halliwell M; Homeida M; Roberts CJ
    Br J Clin Pharmacol; 1977 Jun; 4(3):393P-394P. PubMed ID: 901719
    [No Abstract]   [Full Text] [Related]  

  • 39. Increased values of antipyrine clearance in type IV hyperlipoproteinemia.
    Bedeleanu D; Trif I; Lötsch JC; Cucuianu MP
    Med Interne; 1986; 24(3):183-90. PubMed ID: 3775212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monthly variations in the clearance of antipyrine in the rat.
    Bélanger PM; Doré F; Labrecque G
    Res Commun Chem Pathol Pharmacol; 1984 Oct; 46(1):53-65. PubMed ID: 6505390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.